Activation of Gi-coupled receptors releases a tonic state of inhibited platelet aggregation

Platelets

Volumn 12, Issue 2, 2001, Pages 94-98

  Maayani, S ^a   Schwarz, T ^a   Martinez, R ^a   Tagliente, T M ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ALPHA 2 ADRENERGIC RECEPTOR; CLOPIDOGREL; G PROTEIN COUPLED RECEPTOR; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; PURINE P2 RECEPTOR; RECEPTOR BLOCKING AGENT; SEROTONIN 2A RECEPTOR; ADENOSINE 3' PHOSPHATE 5' PHOSPHATE; ADENOSINE 3'-PHOSPHATE-5'-PHOSPHATE; ADENOSINE PHOSPHATE; ADRENALIN; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTITHROMBOCYTIC AGENT; CANGRELOR; DRUG DERIVATIVE; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; HETEROTRIMERIC GUANINE NUCLEOTIDE BINDING PROTEIN; HIRUDIN DERIVATIVE; LEPIRUDIN; MEMBRANE PROTEIN; P2RY12 PROTEIN, HUMAN; PURINE P2Y1 RECEPTOR; PURINE P2Y12 RECEPTOR; RECOMBINANT PROTEIN; SEROTONIN; SEROTONIN AGONIST; SEROTONIN RECEPTOR; TICLOPIDINE;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHYSIOLOGY; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RICH PLASMA; ADAPTATION; COMPARATIVE STUDY; DRUG EFFECT; DRUG POTENTIATION; MIDDLE AGED;

ADAPTATION, PHYSIOLOGICAL; ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; ADRENERGIC ALPHA-AGONISTS; ADULT; EPINEPHRINE; FEMALE; GTP-BINDING PROTEIN ALPHA SUBUNITS, GI-GO; GTP-BINDING PROTEIN ALPHA SUBUNITS, GQ-G11; HETEROTRIMERIC GTP-BINDING PROTEINS; HIRUDINS; HUMANS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, ADRENERGIC, ALPHA-2; RECEPTORS, PURINERGIC P2; RECEPTORS, SEROTONIN; RECOMBINANT PROTEINS; SEROTONIN; SEROTONIN AGONISTS; TICLOPIDINE;

EID: 0034744933     PISSN: 09537104     EISSN: None     Source Type: Journal    
DOI: 10.1080/09537100020032055     Document Type: Article

References (30)

1. Molecular mechanisms of platelet activation
2. Platelets and the vascular system: Atherosclerosis, thrombosis, myocardial infaction
3. Platelet ADP/purinergic receptors
4. Multiple P2 receptor subtypes on platelets: A new interpretation of their function
5. Ligand specificity and ticlopidine effects distinguish three human platelet ADP receptors
6. 1 purinoceptor in ADP-induced platelet activation
7. Evidence for two distinct G-protein-coupled ADP receptors mediating platelet activation
8. ADP can induce aggregation of human platelets via both P2Y(1) and P-2T receptors
9. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
10. The P-2t antagonist AR-C69931MX is a more effective inhibitor of ADP-induced platelet aggregation than clopidogrel
11. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties
12. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation
13. 1-receptors in human platelets which are pharmacologically distinct from P2Y(ADP)-receptors
14. 1 receptor, necessary but not sufficient to support full ADPinduced platelet aggregation, is not the target of the drug clopidogrel
15. Platelet shape change is mediated by both calcium-dependent and -independent signaling pathways. Role of p160 Rho-associated coiled-coil-containing protein kinase in platelet shape change
16. Molecular mechanism of thromboxane A(2)-induced platelet aggregation. Essential role for p2t(ac) and alpha(2a) receptors
17. 1 receptor
18. Aggregation of blood platelets by adenosine diphosphate and its reversal
19. Measuring platelet aggregation with microplate reader. A new technical approach to platelet aggregation studies
20. Optimisation of platelet aggregometry utilising micotitreplate technology and integrated software
21. Ticlopidine and clopidogrel
22. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel
23. Platelet receptor desensitization induced by elevated prostacyclin levels causes platelet-endothelial cell adhesion
24. Cyclic nucleotides and phosphodiesterases in platelets
25. Interactions of iloprost and sodium nitroprusside on vascular smooth muscle and platelet aggregation
26. Impaired prostaglandin E1/I2 receptor activity of human blood platelets in acute ischemic heart disease
27. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor
28. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium
29. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions
30. Platelet phosphodiesterases